Artificial Intelligence (AI) is rapidly redefining the pharmaceutical industry, reshaping how therapies are discovered, manufactured, distributed, and delivered at global scale. Across discovery, development, manufacturing and supply chains, AI is improving speed, quality and decision‑making at a scale previously unattainable. AI systems are already delivering this impact in practice by accelerating compound discovery, predicting operational deviations before they materialise, and optimising complex global supply chains with unprecedented precision.
The implications extend far beyond operational efficiency. Patients, healthcare providers, and national healthcare systems stand to benefit through faster access to therapies, improved supply resilience, and increasingly personalised models of care. As AI becomes embedded into regulated and safety‑critical workflows, pharma organisations are no longer experimenting at the edges. They are operationalising AI as part of their core digital infrastructure, where AI systems are increasingly treated not just as tools, but as decision‑shaping assets, making trust, resilience and control essential to sustained adoption.
The next stage of AI evolution is Agentic AI. Unlike traditional AI systems that primarily assist decision makers, agentic systems are designed to plan, reason, act and collaborate autonomously in pursuit of defined goals. These agents can trigger workflows, access enterprise tools, coordinate with other agents and adapt dynamically to changing conditions.
In pharma environments, this enables powerful new use cases: autonomous supply chain orchestration, intelligent quality monitoring, adaptive clinical operations and continuous optimisation across complex ecosystems. However, as autonomy scales, so does systemic complexity and risk. Agentic systems introduce new risks through invisible AI‑to‑AI interactions, emergent behaviours and execution paths that are difficult to predict. This fundamentally challenges traditional approval‑based control models, designed for human‑initiated actions rather than continuous machine‑led decision cycles. Human oversight must therefore evolve from periodic supervision to continuous governance observability, and intervention capability.
As AI capabilities accelerate, cybersecurity can no longer be anchored to traditional control assumptions. This is a dual shift. AI is strengthening security operations through faster threat detection, predictive analysis and automated response. At the same time, AI systems, models, datasets, and agentic workflows have themselves become a critical attack surface requiring dedicated protection and governance.
For pharma, this challenge is amplified. Models and datasets increasingly encapsulate some of the industry’s most sensitive intellectual property, proprietary research and regulated information. Agentic AI further expands the attack surface through language‑based interfaces, tool access and autonomous execution. Threats such as data poisoning, model theft, prompt injections, hallucination and misuse of agents are no longer abstract risks. They can lead to corrupted datasets driving incorrect research outcomes, manipulation of models that affect product quality decisions, exposure of sensitive intellectual property, or autonomous systems taking unintended actions that disrupt critical operations. Without purposeful safeguards and resilience, AI can undermine the very outcome it was intended to accelerate.
These dynamics elevate AI security from a technical issue to a board-level strategic imperative. In pharmaceutical organisations, AI increasingly influences regulated decisions related to product quality, patient safety and supply continuity. Expectations around traceability, robustness, logging and human oversight are therefore rising across the AI lifecycle.
Agentic AI sharpens this challenge further. When systems act independently, traditional control models are no longer sufficient. In pharmaceutical organisations, AI governance is no longer solely an IT or innovation responsibility, it is now firmly tied to enterprise trust, resilience and corporate accountability.
Boards and executives must be confident that autonomous behaviour remains bounded, auditable and recoverable if things go wrong. Resilience now depends on the ability to observe, intervene and override autonomous actions in real time, which is critical for protecting innovation, reputation and long‑term competitiveness.
Addressing these risks requires designing trust into AI from the outset. A unified AI control plane provides the foundation, bringing visibility, governance and security together across models, agents and use cases. This represents a fundamental shift in mindset where risk management and security is managed across the lifecycle and it spans data, models, orchestration layers and runtime behaviour.
This includes risk‑based classification aligned with emerging regulatory expectations and cybersecurity obligations; assurance of AI supply chains and third‑party dependencies; and security testing tailored to language‑driven and agentic systems. Continuous monitoring and observability are equally critical, enabling early detection of drift, anomalous behaviour and unintended actions. In agentic environments, observability is fast becoming the primary mechanism through which trust and control are maintained.
AI holds transformative potential for the pharmaceutical industry, but its success depends on trust. Agentic AI magnifies both opportunity and risk, making security, governance and resilience inseparable from innovation. When cyber resilience is treated as a design principle rather than an afterthought, AI can scale safely into the most critical parts of the enterprise.
The organisations that lead this next chapter will not be those that adopt AI fastest, but those that operationalise it responsibly, transparently and resiliently. In life sciences, trust is not a constraint on innovation. It is the strategic accelerator that enables AI to deliver sustainable value for patients, partners and society.